First detection of an invasive Staphylococcus aureus strain (D958) with reduced susceptibility to glycopeptides in Saudi Arabia
- PMID: 20392906
- PMCID: PMC2884509
- DOI: 10.1128/JCM.00954-09
First detection of an invasive Staphylococcus aureus strain (D958) with reduced susceptibility to glycopeptides in Saudi Arabia
Abstract
Strain D958, a methicillin-resistant Staphylococcus aureus strain with reduced susceptibility to vancomycin, was isolated from a 69-year-old Saudi male patient presenting with severe sepsis immediately after admission. Despite high serum levels of vancomycin, the same S. aureus strain was isolated from five blood culture sets during 1 week. Treatment failure under therapeutic levels of vancomycin prompted us to investigate the resistance profile of this strain in further detail. The MIC values for vancomycin as determined by Etest and microdilution were 3.0 and 2.0 mg/liter, respectively, and remained unchanged during the treatment course. The macro-Etest method showed a MIC of 4 mg/liter. The strain showed liquid vancomycin and lysostaphin MBCs of 2.0 and 5.0 mg/liter, respectively. The isolates were confirmed as heterogeneously vancomycin-intermediate S. aureus (hVISA) by vancomycin population analysis profile. The areas under these curves were similar for Mu3 and D958 for vancomycin and teicoplanin (ratio values were 1 and 1.1 for vancomycin and teicoplanin, respectively). Extensive genotyping and molecular characterization demonstrated that the strain harbored a staphylococcal cassette chromosome mec element (SCCmec) type III cassette and was of sequence type ST241, a single-locus variant of the successful multiresistant clone ST239. Microarray results demonstrated that D958 contained numerous resistance determinants (generally plasmid or phage encoded). These results suggest that this strain is constitutively expressing an altered susceptibility to vancomycin. Further studies are warranted to assess the clonal distribution of such strains displaying reduced susceptibility to vancomycin prior to any antimicrobial therapy.
Figures
Similar articles
-
Prevalence of vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous VISA among methicillin-resistant S. aureus with high vancomycin minimal inhibitory concentrations in Taiwan: A multicenter surveillance study, 2012-2013.J Microbiol Immunol Infect. 2016 Oct;49(5):701-707. doi: 10.1016/j.jmii.2015.07.003. Epub 2015 Jul 31. J Microbiol Immunol Infect. 2016. PMID: 26320398
-
Prevalence and molecular characteristics of heterogeneous vancomycin intermediate Staphylococcus aureus in a tertiary care center of northern China.Diagn Microbiol Infect Dis. 2024 Mar;108(3):116180. doi: 10.1016/j.diagmicrobio.2024.116180. Epub 2024 Jan 4. Diagn Microbiol Infect Dis. 2024. PMID: 38183897
-
Evaluation of the Presence and Characterization of Vancomycin-Intermediate and Heterogeneous Vancomycin-Intermediate Level Resistance Among Bloodstream Isolates of Methicillin-Resistant Staphylococcus aureus.Microb Drug Resist. 2020 Mar;26(3):238-244. doi: 10.1089/mdr.2019.0178. Epub 2019 Sep 23. Microb Drug Resist. 2020. PMID: 31545160
-
Occurrence of vancomycin-tolerant and heterogeneous vancomycin-intermediate strains (hVISA) among Staphylococcus aureus causing bloodstream infections in nine USA hospitals.J Antimicrob Chemother. 2009 Nov;64(5):1024-8. doi: 10.1093/jac/dkp319. Epub 2009 Sep 10. J Antimicrob Chemother. 2009. PMID: 19744978
-
Treatment of bacteraemia: meticillin-resistant Staphylococcus aureus (MRSA) to vancomycin-resistant S. aureus (VRSA).Int J Antimicrob Agents. 2013 Jun;42 Suppl:S17-21. doi: 10.1016/j.ijantimicag.2013.04.006. Epub 2013 May 8. Int J Antimicrob Agents. 2013. PMID: 23664580 Review.
Cited by
-
High Bacterial Contamination Load of Self-Service Facilities in Sakaka City, Aljouf, Saudi Arabia, with Reduced Sensitivity to Some Antimicrobials.Microorganisms. 2023 Dec 7;11(12):2937. doi: 10.3390/microorganisms11122937. Microorganisms. 2023. PMID: 38138082 Free PMC article.
-
Eleven-Year surveillance of methicillin-resistant Staphylococcus aureus infections at an Academic Health Centre.J Prev Med Hyg. 2022 Apr 26;63(1):E132-E138. doi: 10.15167/2421-4248/jpmh2022.63.1.2387. eCollection 2022 Mar. J Prev Med Hyg. 2022. PMID: 35647383 Free PMC article.
-
Reduced Susceptibility and Resistance to Vancomycin of Staphylococcus aureus: A Review of Global Incidence Patterns and Related Genetic Mechanisms.Cureus. 2021 Oct 20;13(10):e18925. doi: 10.7759/cureus.18925. eCollection 2021 Oct. Cureus. 2021. PMID: 34812309 Free PMC article. Review.
-
Vancomycin intermediate resistant Staphylococcus aureus in the nasal cavity of asymptomatic individuals: a potential public health challenge.Afr Health Sci. 2020 Sep;20(3):1109-1117. doi: 10.4314/ahs.v20i3.12. Afr Health Sci. 2020. PMID: 33402955 Free PMC article.
-
Global prevalence and distribution of vancomycin resistant, vancomycin intermediate and heterogeneously vancomycin intermediate Staphylococcus aureus clinical isolates: a systematic review and meta-analysis.Sci Rep. 2020 Jul 29;10(1):12689. doi: 10.1038/s41598-020-69058-z. Sci Rep. 2020. PMID: 32728110 Free PMC article.
References
-
- Al-Mustafa, Z. H., and M. S. Al-Ghamdi. 2002. Use of antibiotics in the poultry industry in Saudi Arabia: implications for public health. Ann. Saudi Med. 22:4-7. - PubMed
-
- Andrade-Baiocchi, S., M. C. Tognim, O. C. Baiocchi, and H. S. Sader. 2003. Endocarditis due to glycopeptide-intermediate Staphylococcus aureus: case report and strain characterization. Diagn. Microbiol. Infect. Dis. 45:149-152. - PubMed
-
- Appelbaum, P. C. 2006. MRSA—the tip of the iceberg. Clin. Microbiol. Infect. 12(Suppl. 2):3-10. - PubMed
-
- Ariza, J., M. Pujol, J. Cabo, C. Pena, N. Fernandez, J. Linares, J. Ayats, and F. Gudiol. 1999. Vancomycin in surgical infections due to methicillin-resistant Staphylococcus aureus with heterogeneous resistance to vancomycin. Lancet 353:1587-1588. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical